Use of recombinant interleukin-2 for intrapleural therapy of tumor-associated pleurisy.
Clinical efficiency of low dose Roncoleukin was studied in 30 patients with metastatic exudative pleurisy. Intrapleural therapy proved to be highly effective (overall effect reached 84%), was well tolerated, and improved patients' quality of life.